AbbVie Inc.: Target Price Consensus and Analysts Recommendations | ABBV | US00287Y1091

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

180.37USD

Average target price

210.01USD

Spread / Average Target

+16.43%

High Price Target

250.00USD

Spread / Highest target

+38.60%

Low Price Target

173.00USD

Spread / Lowest Target

-4.09%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Citigroup
Morgan Stanley
Berenberg Bank
Redburn Atlantic
Wells Fargo Securities
TD Cowen
HSBC
Daiwa Securities
UBS
Truist Securities
Deutsche Bank Securities
Leerink Partners
Goldman Sachs
Guggenheim
Raymond James
Wolfe Research
Piper Sandler
JPMorgan Chase
BMO Capital
Argus
Cantor Fitzgerald
Evercore ISI
Barclays
Mizuho Securities
Morningstar
William Blair & Co.
BofA Securities
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Cowen
Redburn
SVB Leerink
RBC Capital Markets

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2025-04-24 pm EDT			5-day change	1st Jan Change
180.37 ^USD	+1.88%		+4.27%	+1.50%

Apr. 24	AbbVie Submits Biologics License Application to FDA for Glabellar Lines Treatment	MT
Apr. 24	AbbVie Submits Biologics License Application To U.S. FDA For Trenibotulinumtoxine (TrenibotE) For The Treatment Of Glabellar Lines	RE

Citigroup Adjusts Price Target on AbbVie to $210 From $215, Keeps Buy Rating	Apr. 11	MT
Morgan Stanley Adjusts Price Target on AbbVie to $241 From $239, Keeps Overweight Rating	Apr. 09	MT
Berenberg Adjusts Price Target on AbbVie to $195 From $165, Maintains Hold Rating	Mar. 12	MT
Redburn Atlantic Adjusts Price Target on AbbVie to $234 From $216	Mar. 10	MT
Wells Fargo Adjusts Price Target on AbbVie to $240 From $210, Keeps Overweight Rating	Mar. 05	MT
TD Cowen Adjusts Price Target on AbbVie to $250 From $225, Maintains Buy Rating	Mar. 04	MT
HSBC Adjusts AbbVie Price Target to $230 From $220, Maintains Buy Rating	Feb. 27	MT
Daiwa Securities Adjusts Price Target on AbbVie to $190 From $180, Keeps Neutral Rating	Feb. 04	MT
UBS Adjusts Price Target on AbbVie to $190 From $181, Maintains Neutral Rating	Feb. 03	MT
Truist Securities Adjusts AbbVie Price Target to $217 From $211, Maintains Buy Rating	Feb. 03	MT
Deutsche Bank Adjusts AbbVie Price Target to $173 From $177, Maintains Hold Rating	Feb. 03	MT
Leerink Adjusts Price Target on AbbVie to $210 From $206, Maintains Outperform Rating	Feb. 03	MT
Goldman Sachs Adjusts Price Target on AbbVie to $212 From $208, Keeps Buy Rating	Feb. 03	MT
Guggenheim Adjusts Price Target on AbbVie to $214 From $212, Keeps Buy Rating	Feb. 03	MT
Raymond James Adjusts Price Target on AbbVie to $220 From $218, Keeps Outperform Rating	Feb. 03	MT
Wolfe Research Adjusts Price Target on AbbVie to $220 From $205, Keeps Outperform Rating	Feb. 03	MT
Wells Fargo Adjusts Price Target on AbbVie to $210 From $195, Keeps Overweight Rating	Feb. 03	MT
Citigroup Adjusts Price Target on AbbVie to $205 From $215, Maintains Buy Rating	Jan. 28	MT
Piper Sandler Adjusts Price Target on AbbVie to $227 From $220, Keeps Overweight Rating	Jan. 27	MT
Goldman Sachs Adjusts Price Target on AbbVie to $208 From $205, Keeps Buy Rating	Jan. 27	MT
Guggenheim Adjusts Price Target on AbbVie to $212 From $221, Maintains Buy Rating	Jan. 17	MT
Redburn Atlantic Adjusts Price Target on AbbVie to $216 From $214, Maintains Buy Rating	Jan. 17	MT
Redburn Atlantic Adjusts Price Target on AbbVie to $214 From $216, Keeps Buy Rating	Jan. 10	MT
Truist Trims Price Target on AbbVie to $211 From $215, Keeps Buy Rating	Jan. 08	MT
Piper Sandler Adjusts AbbVie Price Target to $220 From $212, Maintains Overweight Rating	Dec. 17	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	ABBVIE INC.					+16.43%
	ELI LILLY AND COMPANY					+17.32%
	JOHNSON & JOHNSON					+9.63%
	NOVO NORDISK A/S					+77.23%
	ROCHE HOLDING AG					+19%
	ASTRAZENECA PLC					+29.86%
	NOVARTIS AG					+6.35%
	MERCK & CO., INC.					+35.73%
	AMGEN INC.					+12.43%
	GILEAD SCIENCES, INC.					+7.02%
	Average					+23.10%
	Weighted average by Cap.					+22.78%

Consensus AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

Analysts' recommendations: AbbVie Inc.

Sector Comparison:

Analysts' Consensus

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Ratings

Quarterly revenue - Rate of surprise

Consensus AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

Analysts' recommendations: AbbVie Inc.

Sector Comparison: HealthcarePharmaceuticals & Medical ResearchPharmaceuticalsPharmaceuticalsOther Pharmaceuticals

Analysts' Consensus

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Ratings

Quarterly revenue - Rate of surprise

Sector Comparison: